Clinical trial · Interventional
Bryostatin-1 in Treating Patients With Recurrent Non-Hodgkin's Lymphoma
PHASE II EVALUATION OF BRYOSTATIN-1 (NSC 339555) IN NON-HODGKIN'S LYMPHOMA
NCT00002725CI-TRIAL-00009306completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Phase II trial to study the effectiveness of bryostatin-1 in treating patients with recurrent non-Hodgkin's lymphoma. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| bryostatin 1 | Drug | — | UNRESOLVED |
| chemotherapy | Drug | Chemotherapy | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Arm I
- description
- Single-Agent Chemotherapy/Differentiation Therapy. Bryostatin 1, BRYO, NSC-339555.
- interventionNames
- Drug: bryostatin 1
- Drug: chemotherapy
Primary outcomes (0)
[]Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically confirmed non-Hodgkin's lymphoma * Working formulation low-, intermediate-, and high-grade histologies eligible * Mantle cell and marginal zone lymphoma eligible * Relapse after at least 1 doxorubicin-containing regimen required * No more than 2 prior chemotherapy regimens * One prior biologic therapy in addition to the 2 prior chemotherapy regimens allowed * No prior bone marrow transplantation * Ineligible for treatment on higher priority protocols * Patients eligible for bone marrow transplantation may be treated to reduce tumor bulk * Bidimensionally measurable disease required * No history of primary or metastatic CNS disease PATIENT CHARACTERISTICS: * Age: Any age * Performance status: Zubrod 0-2 * Life expectancy: Greater than 12 weeks * Absolute neutrophil count at least 1,000/mm3 * Platelet count at least 100,000/mm3 * Bilirubin no greater than 1.8 mg/dL * Transaminases no greater than 2.5 times normal * Creatinine no greater than 1.5 mg/dL OR creatinine clearance greater than 70 mL/min * No HIV antibody * No serious intercurrent illness * No pregnant or nursing women * Effective contraception required of fertile patients throughout study and for 1 year thereafter PRIOR CONCURRENT THERAPY: -At least 4 weeks since prior therapy (6 weeks since mitomycin) and recovered
References
Publications (0)
Data not yet available
No reference posted for this study.